Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

DPAG scientists across four research groups were highlighted at the major annual European Society of Cardiology basic science conference (FCVB 2022). Congratulations are in order for Dr KC Park on receiving the Young Investigator Award and to Dr Elisabetta Gamen on winning the Moderated Poster Prize.

L-R: KC Park, Elisabetta Gamen and Milda Folkmanaite

DPAG researchers from the Heather, Riley, Swietach and Zaccolo groups attended the prestigious Frontiers in CardioVascular Biomedicine (FCVB) 2022, held in Budapest, Hungary from Friday 29 April until Sunday 1 May. FCVB showcases the best, the latest and the most exciting findings and ideas across the entire spectrum of cutting-edge basic and translational cardiovascular research.

Associate Professor Lisa Heather was an invited speaker to the conference, delivering “Glucose and lipids: when more is not better” on Saturday 30 April 2022. Dr KC Park and Dr Elisabetta Gamen received Travel Awards from the European Society of Cardiology (ESC) to attend the conference.

Dr KC Park, postdoctoral research scientist in the Swietach Group, won first place in the Young Investigator Award session. Competitors for this prestigious award are selected for the outstanding quality of their work and present their own original research to a panel of world-renowned experts.

Dr Park presented “Epigenetic changes in the heart triggered by disrupted propionate handling”, which relayed his research into understanding how the ubiquitous metabolite propionate affects heart function. “Whilst propionate concentrations are usually kept low by the mitochondrial enzyme PCC, it can accumulate when PCC activity is reduced. The most extreme example of propionate accumulation occurs in the rare disease propionic acidaemia (PA). Critically, many PA deaths relate to heart problems, suggesting cardiac disease is a major biological consequence, driven by elevated propionate. Using a mouse model of PA, we found that propionate accumulation has profound effects on cardiac gene expression, which involved histone modifications, and were associated with cardiac dysfunction.”

Dr Park joined DPAG in 2017 as a DPhil student in the Swietach Group as part of the British Heart Foundation 4-year Non-Clinical PhD Studentship in Cardiovascular Science. His research investigated the effects of dysregulated propionate metabolism on cardiac physiology. After pausing his project to carry out COVID-19 research during the pandemic, he completed his DPhil in 2021, commencing his first postdoctoral position under Professor Swietach. He is funded by the Propionic Acidemia Foundation and a Career Development Award from the Oxford BHF Doctoral Training Programme. Dr Park adds this Young Investigator Award to the Paul Dudley White International Scholar Award received in July 2020 from the American Heart Foundation.

On receiving the Young Investigator Award, Dr Park would like to acknowledge the mentorship and collaborations of Dr Nicolas Crump and Associate Professor Thomas Milne from the Weatherall Institute of Molecular Medicine (WIMM) and the mentorship and supervision of Dr Alzbeta Hulikova, Associate Professor Nicola Smart and his main supervisor, Professor Pawel Swietach.

Dr Elisabetta Gamen, postdoctoral research scientist in the Riley Group, and Milda Folkmanaite, DPhil student in the Zaccolo Group, presented in the Moderated Poster sessions. Dr Gamen won Best Moderated Poster with “Re-activation of HIF signalling pathway in the epicardium improves heart regeneration after myocardial infarction”.

Dr Gamen’s poster outlined work showing that hypoxia signaling is important for epicardial activation, during both heart development and repair. “In mouse, this signalling gradually decreases during the first week of life concomitantly with epicardial inactivation. Genetical and pharmacological stabilisation of HIF signaling proved to be effective in re-activating the epicardium and improving heart function in a neonatal mouse model of myocardial infarction.”

More information on FCVB 2022 can be found on the ESC website.

Similar stories

Joaquim Vieira brings heart regeneration research to the public at Pint of Science

Pint of Science is the world’s largest public science festival bringing researchers to local pubs, cafes and spaces to share their scientific discoveries with the public.

RDM researchers awarded £2million MRC grant

Researchers at the Cardiovascular Clinical Research Facility (CCRF) have won a five year MRC funding programme to help understand how high blood pressure (hypertension) during pregnancy affects the heart, brain and blood vessels throughout the life of women, as well as the children born after such a pregnancy.

Study indicates reasons for decline in death rates from heart attacks

A new study involving Oxford Population Health researchers finds that both prevention and improved treatments have helped reduce deaths from heart attacks - but the relative importance of each varies by country, age and sex.

Commercial development of therapeutic anti-inflammatory peptide begins

An Oxford BHF CRE “Pump Priming” award to Professor Shoumo Bhattacharya and his research group led to a great return on investment with this exclusive licensing agreement for their innovative research.

Dr Qiang Zhang wins Society for Cardiovascular Magnetic Resonance Early Career Award 2022

Many congratulations to Dr Qiang Zhang, Oxford BHF CRE Transition Fellow, who has won a prestigious award for his work in developing a groundbreaking technology for detecting scar in the myocardium

RDM researchers test potential treatment for fatigue in long COVID patients

The Radcliffe Department of Medicine’s Dr Betty Raman is leading a new a phase 2a clinical trial to investigate whether a drug could treat the fatigue and muscle weakness experienced by many patients who have recovered from COVID.